CN106905427A - 用于抑制炎症的肽 - Google Patents
用于抑制炎症的肽 Download PDFInfo
- Publication number
- CN106905427A CN106905427A CN201710090305.XA CN201710090305A CN106905427A CN 106905427 A CN106905427 A CN 106905427A CN 201710090305 A CN201710090305 A CN 201710090305A CN 106905427 A CN106905427 A CN 106905427A
- Authority
- CN
- China
- Prior art keywords
- peptide
- amino acid
- seq
- side chain
- positively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161454342P | 2011-03-18 | 2011-03-18 | |
US61/454342 | 2011-03-18 | ||
CN201280013797.8A CN103429610B (zh) | 2011-03-18 | 2012-03-16 | 用于抑制炎症的肽 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280013797.8A Division CN103429610B (zh) | 2011-03-18 | 2012-03-16 | 用于抑制炎症的肽 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106905427A true CN106905427A (zh) | 2017-06-30 |
Family
ID=46879976
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280013797.8A Active CN103429610B (zh) | 2011-03-18 | 2012-03-16 | 用于抑制炎症的肽 |
CN201710090305.XA Pending CN106905427A (zh) | 2011-03-18 | 2012-03-16 | 用于抑制炎症的肽 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280013797.8A Active CN103429610B (zh) | 2011-03-18 | 2012-03-16 | 用于抑制炎症的肽 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9018169B2 (zh) |
EP (2) | EP2685999A4 (zh) |
JP (1) | JP6158097B2 (zh) |
KR (1) | KR101993937B1 (zh) |
CN (2) | CN103429610B (zh) |
AU (1) | AU2012231268B2 (zh) |
CA (1) | CA2830259C (zh) |
ES (1) | ES2686274T3 (zh) |
SG (1) | SG192773A1 (zh) |
WO (1) | WO2012129077A2 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201702769QA (en) | 2014-10-08 | 2017-05-30 | Univ North Carolina | Improved peptide inhibitors of sodium channels |
JP6764679B2 (ja) | 2015-05-27 | 2020-10-07 | キリンホールディングス株式会社 | ペプチドを含む炎症抑制のための組成物 |
EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
WO2018140563A1 (en) | 2017-01-26 | 2018-08-02 | Duke University | Use of apoe mimetic peptides for reducing the likelihood of epileptogenesis |
CN109942714B (zh) * | 2019-04-02 | 2022-07-08 | 中国药科大学 | 一种功能多肽及应用 |
CN111956781B (zh) * | 2019-05-20 | 2023-11-17 | 益承康泰(厦门)生物科技有限公司 | 一种多肽在治疗眼部炎症药物中的应用 |
CA3225275A1 (en) * | 2021-07-08 | 2023-01-12 | Lung Therapeutics, Inc. | Epithelial sodium channel (enac) inhibitor conjugates and methods for use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003026479A2 (en) * | 2001-09-21 | 2003-04-03 | Cognosci, Inc. | Methods of suppressing microglial activation |
US20030077583A1 (en) * | 1997-09-17 | 2003-04-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02004283A (es) | 1999-10-29 | 2002-10-17 | Chiron Spa | Peptidos antigenicos neisseriales. |
US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
AU2001275423B2 (en) * | 2000-06-09 | 2007-01-11 | Regulon, Inc. | Encapsulation of polynucleotides and drugs into targeted liposomes |
PL362699A1 (en) | 2001-03-08 | 2004-11-02 | Merck Patent Gmbh | Modified protamine with reduced immunogenicity |
US7033991B2 (en) * | 2001-07-16 | 2006-04-25 | Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College | Inhibiting furin with polybasic peptides |
CN1555272A (zh) * | 2001-07-31 | 2004-12-15 | �ո��� | 调节免疫应答的组合物和方法 |
US7820374B2 (en) * | 2001-11-21 | 2010-10-26 | Erasmus Universiteit Rotterdam | Detection methods based on HR23 protein binding molecules |
CN1650005B (zh) | 2002-04-25 | 2010-12-08 | 东亚合成株式会社 | 抗菌性多肽及其应用 |
CA2514938A1 (en) | 2003-01-31 | 2004-10-14 | Ethicon, Inc. | Method for detecting escherichia coli |
US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
EP1624886A2 (en) | 2003-05-12 | 2006-02-15 | Expressive Constructs, Inc. | Methods for increasing cell and tissue viability |
WO2004111636A2 (en) * | 2003-06-17 | 2004-12-23 | Vib Vzw | Peptide combos and their uses |
EP1762626B1 (en) | 2003-09-02 | 2010-12-15 | Systagenix Wound Management IP Co. BV. | Signal amplification using a synthetic zymogen |
WO2005035003A2 (en) | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
WO2005042771A2 (en) | 2003-11-03 | 2005-05-12 | Ethicon, Inc. | Colorimetric substrates, colorimetric sensors, and methods of use |
WO2007092360A2 (en) | 2006-02-02 | 2007-08-16 | Ethicon, Inc. | Diagnostics and methods for removal and detection of interferents |
WO2007092909A2 (en) | 2006-02-07 | 2007-08-16 | Expressive Constructs, Inc. | Molecular interaction sensors |
ES2497441T3 (es) | 2006-08-21 | 2014-09-22 | The University Of British Columbia | Péptidos inmunomoduladores catiónicos pequeños |
EP2030980A1 (en) | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
US9303063B2 (en) | 2011-03-18 | 2016-04-05 | Duke University | Peptide compounds for suppressing inflammation |
WO2013034982A2 (en) | 2011-09-09 | 2013-03-14 | The University Of British Columbia | Immunomodulatory peptides for treatment of progressive neurodegenerative diseases |
-
2012
- 2012-03-16 JP JP2013558202A patent/JP6158097B2/ja active Active
- 2012-03-16 KR KR1020137023270A patent/KR101993937B1/ko active IP Right Grant
- 2012-03-16 ES ES15161584.6T patent/ES2686274T3/es active Active
- 2012-03-16 AU AU2012231268A patent/AU2012231268B2/en active Active
- 2012-03-16 CN CN201280013797.8A patent/CN103429610B/zh active Active
- 2012-03-16 EP EP12760270.4A patent/EP2685999A4/en not_active Withdrawn
- 2012-03-16 EP EP15161584.6A patent/EP2929890B1/en active Active
- 2012-03-16 CN CN201710090305.XA patent/CN106905427A/zh active Pending
- 2012-03-16 SG SG2013061742A patent/SG192773A1/en unknown
- 2012-03-16 WO PCT/US2012/029392 patent/WO2012129077A2/en active Application Filing
- 2012-03-16 CA CA2830259A patent/CA2830259C/en active Active
- 2012-03-16 US US13/981,238 patent/US9018169B2/en active Active
-
2015
- 2015-03-18 US US14/661,243 patent/US9687521B2/en active Active
-
2017
- 2017-06-02 US US15/612,641 patent/US20170274037A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077583A1 (en) * | 1997-09-17 | 2003-04-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2003026479A2 (en) * | 2001-09-21 | 2003-04-03 | Cognosci, Inc. | Methods of suppressing microglial activation |
Non-Patent Citations (1)
Title |
---|
LYNCH JR等: "APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory Response", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Also Published As
Publication number | Publication date |
---|---|
AU2012231268B2 (en) | 2017-02-02 |
KR20140026373A (ko) | 2014-03-05 |
CN103429610A (zh) | 2013-12-04 |
ES2686274T3 (es) | 2018-10-17 |
US20170274037A1 (en) | 2017-09-28 |
US9687521B2 (en) | 2017-06-27 |
CA2830259C (en) | 2021-06-29 |
EP2929890B1 (en) | 2018-06-27 |
KR101993937B1 (ko) | 2019-06-27 |
CA2830259A1 (en) | 2012-09-27 |
WO2012129077A2 (en) | 2012-09-27 |
CN103429610B (zh) | 2017-03-01 |
EP2685999A2 (en) | 2014-01-22 |
SG192773A1 (en) | 2013-09-30 |
WO2012129077A3 (en) | 2012-11-15 |
US9018169B2 (en) | 2015-04-28 |
JP2014509594A (ja) | 2014-04-21 |
AU2012231268A1 (en) | 2013-08-22 |
EP2685999A4 (en) | 2015-07-15 |
US20140038898A1 (en) | 2014-02-06 |
JP6158097B2 (ja) | 2017-07-05 |
US20150250847A1 (en) | 2015-09-10 |
EP2929890A1 (en) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103429610B (zh) | 用于抑制炎症的肽 | |
CN103998053B (zh) | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 | |
CN110290799A (zh) | 用于治疗肺部炎性病症的方法 | |
CN106913865A (zh) | 使用白细胞介素‑10治疗疾病和病症的方法 | |
US20210395342A1 (en) | Peptide compounds for suppressing inflammation | |
US10729636B2 (en) | Compositions comprising peptide WKDEAGKPLVK | |
US6699973B1 (en) | Antibodies to peptides that target GIT receptors and related methods | |
WO2021233885A1 (en) | Mimotope peptides of the spike protein from the sars-cov-2 virus | |
JP5208135B2 (ja) | 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物 | |
CN103764669B (zh) | 抗炎药物产品 | |
ES2256070T3 (es) | Actividad antimicrobiana de la primera agrupacion cationica de lactoferrina humana. | |
CN107454846A (zh) | 修饰的肽及其治疗慢性炎性疾病的用途 | |
KR101293777B1 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 | |
CN107206046A (zh) | 改良的钠通道的肽抑制剂 | |
KR101301417B1 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 | |
CN101602793B (zh) | 用于预防和/或治疗类风湿性关节炎的免疫调节多肽及其应用 | |
US20200031866A1 (en) | Peptide inhibitors of sodium channels | |
WO2013134292A2 (en) | Compositions and methods for mitigation of inflammasome activation | |
WO2024050300A2 (en) | Synthetic surfactants for inhibiting coronavirus infection | |
WO2015118546A1 (en) | Mucolytic compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170630 Assignee: Beijing C&N International Sci-Tech Co., Ltd. Assignor: Eages LLC Contract record no.: 2017990000378 Denomination of invention: Peptides for suppressing inflammation License type: Exclusive License Record date: 20170920 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Beijing C&N International Sci-Tech Co., Ltd. Assignor: Eages LLC Contract record no.: 2017990000378 Date of cancellation: 20190409 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170630 Assignee: Guangdong Quapeng Peptide Ling Biological Technology Co., Ltd. Assignor: Eages LLC Contract record no.: 2019990000128 Denomination of invention: Peptides for suppressing inflammation License type: Exclusive License Record date: 20190428 |